NCGC Projects

A National Research and Innovation Platform for Personalized Cancer Medicine

The project will establish the required general technology, methodology and interpretation procedures, which will be commonly shared, for utilizing the mutation profile of the tumor to guide the adaptation of cancer treatment to the individual patient.

Malignant neoplasm mole (melanoma)

Our first project was the sequencing of all genes (EKSOM) in 114 melanomas and normal samples from all patients. These data are now being analyzed. The project is performed at Haukeland University Hospital.

Colorectal cancer

The exomes of 100 pairs of normal/cancer patient samples have been sequenced, and are now being analyzed for mutations. This project is performed at Oslo University Hospital.

Multiple Myeloma

Myelomatosis and chronic lymphatic leukaemia (CLL) are the most common cancers of the blood, with 370 annual new cases.

Lymphoma

We are about to determine the sequence of all genes in several subtypes of Lymphoma. The project is performed at Oslo University Hospital.

Leukaemia

We are currently planning the sequencing of the eksom of groups of specifically selected subtypes of leukaemia. The project is based at Haukeland University Hospital.

Sarcoma

In collaboration with the clinical sarcoma groups in all Norwegian health regions, we are initiating a population-based investigation of tumor mutations in Norwegian patients with high-grade sarcoma, and the hope is to identify mutated genes which are currently subject to targeted therapies in other cancer types, thereby opening for the opportunity to utilise these treatments for sarcoma patients.

Prostate Cancer

Heterogeneity of genetic changes in multifocal prostate cancer

Breast cancer

A study of metastatic breast cancer is being planned.

Ovarian Cancer

Ovarian Cancer is the most lethal gynecological cancer. The symptoms of ovarian cancer come late and are often non-specific. Consequently, approximately two-thirds of the patients are diagnosed with advanced stages (FIGO stage III or IV).

Bioinformatics

A crucial part of the work is to analyse the DNA code in the most efficient and precise way. Each step of the process requires optimisation to prevent errors in the readout.

Technology

A crucial part of the work is to analyse the DNA code in the most efficient and precise way. Each step of the process requires optimisation to prevent errors in the readout.

Health economics

The goal is to achieve the best possible health care for all people of the society with the limited resources available to health care.

Ethics

The work-package for ethics, law and public aspects is led by professor Jan Helge Solbakk at the public health department at the University of Oslo. The Norwegian Biotechnology Advisory Board and the Oslo Cancer Cluster are also involved in this work-package.

Public dialogs

The Norwegian Biotechnology Advisory Board led by Director Sissel Rogne participates in the ethical research projects as well as the public discussions. The Cancer Society contributes wit the perspective of the patient.

Law

The project «Legal Regulation of Information Processing Relating to Personalized Cancer Medicine» is led by Professor Jan Helge Solbakk. The project is a collaboration between The Centre for Medical Ethics at The Medical Faculty, University of Oslo and The Norwegian Research Center for Computers and Law at The Faculty of Law, University of Oslo.

Innovative networks

The Oslo Cancer Cluster actively supports the Norwegian Cancer Genomics Consortium (NCGC), and has done so since the start. The Oslo Cancer Cluster Management Team in close collaboration with several members, was vital in supporting the birth of the NCGC and is actively promoting the consortium and its activities through its meeting places and networks - both national and international. Personalized Cancer Medicine is an area of great importance for the Oslo Cancer Cluster, and one of the major projects we work on. The area is of key importance for all member groups, from academic researchers, to clinicians, biotech and pharma companies developing novel cancer treatments in preclinical and clinical research. A personal approach to cancer care improves patient care, and tailored treatment based on individual diagnostics, can address existing and future challenges of our health care system.

Associated projects

NCGC wants to collaborate with all the national cancer research groups and other relevant groups to ensure a future use of the platform once fully generated.

NCGC Intranett